AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 20642487
Drug: milnacipran 200
RxNorm normalized name: MILNACIPRAN
DrugBank: Milnacipran (DB04896)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: milnacipran 200 mg/day
Trial: 20642487
Drug: milnacipran 100
RxNorm normalized name: milnacipran 100 mg oral tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: milnacipran 100 mg/day
Trial: 15748230
Drug: Low-dose DX-9065a
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose DX-9065a
Trial: 15748230
Drug: High-dose DX-9065a
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose DX-9065a
Trial: 12572381
Drug: Kesuning Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Kesuning Granule (KSNG) 8 g, three times a day
Trial: 12572381
Drug: Jinbei Tankeqing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Jinbei Tankeqing Granule (JBTKQ) 7 g, three times a day
Trial: 9892479
Drug: Captopril (ACE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Captopril (ACE inhibitor) therapy administered 48 to 72 hours postoperatively in group B (103 patients)
Trial: 709092
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg cholesterol diet
Trial: 709092
Drug: 600 mg
RxNorm normalized name: mesna 600 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 mg cholesterol diet
Trial: 709092
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg cholesterol diet (after 600 mg diet)
Trial: 709092
Drug: Plant sterols
RxNorm normalized name: Plant Sterols/Stanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterols (3 g daily) added to 100 mg cholesterol diet
Trial: 709092
Drug: Plant sterols
RxNorm normalized name: Plant Sterols/Stanol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Plant sterols (3 g daily) added to 600 mg cholesterol diet
Trial: 24893708
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg atomoxetine
Trial: 8848904
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oral promethazine (10 mg) and transdermal scopolamine (1.5 mg)
Trial: 8848904
Drug: Oral diazepam
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral diazepam (5‐15 mg)
Trial: 8848904
Drug: Oral promethazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral promethazine (10 mg)
Trial: 8848904
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of oral promethazine and transdermal scopolamine
Trial: 2193273
Drug: Daily objective
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily objective uterine activity data
Trial: 358765
Drug: Ferro-Retard (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferro-Retard (100 mg ferrous sulphate)
Trial: 358765
Drug: Ferro-Retard (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ferro-Retard (100 mg Fe2+)
Trial: 12520172
Drug: Sustained release
RxNorm normalized name: Sustained Release Buccal Tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sustained release tablets
Trial: 358765
Drug: Placebo, rapidly
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, rapidly disintegrating and sustained release ferrous sulphate tablets
Trial: 31786869
Drug: Cisplatin and
RxNorm normalized name: A micelle drug formulation composed of cisplatin and mPEG-poly(l-Glu) diblock copolymer with 1,3-propanediyl linkagecisplatin is incorporated in polymeric micelles via polymer-metal complex formation with cis-geometry of PT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cisplatin and nimotuzumab combined with concurrent chemoradiotherapy
Trial: 31786869
Drug: Cisplatin combined
RxNorm normalized name: Cisplatin
DrugBank: Cisplatin (DB00515)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Cisplatin combined with concurrent chemoradiotherapy
Trial: 25483419
Drug: Intravenous labetalol
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous labetalol (L)
Trial: 25483419
Drug: Intravenous hydralazine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous hydralazine (H)
Trial: 18332608
Drug: Pitavastatin treatment
RxNorm normalized name: Pitavastatin
DrugBank: Pitavastatin (DB08860)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pitavastatin treatment
Trial: 16279903
Drug: 4.8 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4.8 g/day mesalamine (800 mg tablet)
Trial: 16279903
Drug: 2.4 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.4 g/day mesalamine (400 mg tablet)
Trial: 8142092
Drug: 3 mg
RxNorm normalized name: boron 3 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 mg of epidural morphine
Trial: 3150126
Drug: Magnesium Valproate
RxNorm normalized name: magnesium valproate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Magnesium Valproate (Mg VPA)
Trial: 25595308
Drug: Standard fluid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard fluid therapy (Control)
Trial: 23750460
Drug: Internet-delivered cognitive
RxNorm normalized name: DELIVER
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Internet-delivered cognitive behavioral treatment based on exposure exercises (ICBT)
Trial: 21915490
Drug: Multidisciplinary rehabilitation
RxNorm normalized name: GLUTATHIONE 12.5 g in 100 mL ORAL LIQUID [K2LTS Brain Rehabilitation]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multidisciplinary rehabilitation program (12-week stimulation and psychoeducational program, administered twice a week during 6.5-hour gatherings)
Trial: 30450213
Drug: High intensity
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High intensity interval training (HIIT) on a cycle ergometer, thrice weekly for 8 weeks
Trial: 30450213
Drug: Weekly contact
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Weekly contact with investigators
Trial: 23877339
Drug: Eribulin mesylate
RxNorm normalized name: Eribulin Mesylate
DrugBank: Eribulin (DB08871)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Eribulin mesylate (1.4 mg/m², 2-5 min intravenous on days 1 and 8)
Trial: 23877339
Drug: Ixabepilone (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ixabepilone (40 mg/m², 3 h intravenous on day 1)
Trial: 19919966
Drug: Home orthostatic
RxNorm normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Home orthostatic training (HOT) for 40 min daily for 6 months
Trial: 19919966
Drug: Sham training
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sham training for 10 min daily for 6 months
Trial: 18426147
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (NS) plus loratadine, 200 microg + 10 mg
Trial: 18426147
Drug: Mometasone furoate
RxNorm normalized name: Mometasone Furoate
DrugBank: Mometasone furoate (DB14512)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mometasone furoate nasal spray (NS), 200 microg
Trial: 16682384
Drug: Triple antiplatelet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Triple antiplatelet therapy (aspirin, clopidogrel 300 mg, and Tirofiban)
Trial: 16682384
Drug: Dual antiplatelet
RxNorm normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dual antiplatelet therapy (aspirin, clopidogrel 600 mg)
Trial: 22186694
Drug: Sandostatin LAR
RxNorm normalized name: Sandostatin LAR
DrugBank: Octreotide (DB00104)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Sandostatin LAR 30 mg injection once every 4 weeks for 6 doses (n = 35)
Trial: 7617237
Drug: Dobutamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dobutamine infusion at 3 mu/kg/min, started before anesthesia and modulated during the operation based on monitoring values.
Trial: 7617237
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no dobutamine infusion), underwent the same anesthesiological procedure without receiving the drug.
Trial: 1978487
Drug: Controlled release
RxNorm normalized name: EpiCeram Controlled Release Skin Barrier Emulsion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled release (CR) 400 mg once daily
Trial: 1978487
Drug: Immediate release
RxNorm normalized name: Namenda, immediate release oral kit
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Immediate release (IR) 200 mg twice daily
Trial: 29401353
Drug: Transcendental Meditation
RxNorm normalized name: benzalkonium chloride Topical Foam [Meditize]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcendental Meditation (TM) practice; full-dose (two 20-min sessions per day) and half-dose (one 20-min session per day) groups.
Trial: 29401353
Drug: Transcendental Meditation
RxNorm normalized name: benzalkonium chloride Topical Foam [Meditize]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transcendental Meditation (TM) practice; full-dose group vs half-dose group.
Trial: 24124961
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec and insulin aspart (IDegAsp)
Trial: 19778808
Drug: L-thyroxine (6.25-25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: L-thyroxine (6.25-25 microg daily)
Trial: 15908661
Drug: GemOx (gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GemOx (gemcitabine 1 g/m2 as a 100‐minute infusion on day 1 and oxaliplatin 100 mg/m2 as a 2‐hour infusion on day 2 every 2 weeks)
Trial: 15908661
Drug: Gem (gemcitabine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gem (gemcitabine 1 g/m2 as a weekly 30‐minute infusion)
Trial: 9617916
Drug: Bromocriptine (DA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromocriptine (DA agonist)
Trial: 9617916
Drug: Fenfluramine (serotonin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fenfluramine (serotonin agonist)
Trial: 144842
Drug: SH B
RxNorm normalized name: BSH BTC
DrugBank: Dental Mesenchymal Pulp Stem Cells (DB15737)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SH B 209 AB (antiandrogen preparation containing cyproterone acetate)
Trial: 144842
Drug: Neogynon (ovulation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Neogynon (ovulation inhibitor with no antiandrogenic effect)
Trial: 28866652
Drug: 5 mg/day
RxNorm normalized name: Lyllana 0.05 MG/Day Transdermal Patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg/day folic acid
Trial: 28866652
Drug: 0.5 mg/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5 mg/day folic acid
Trial: 26521569
Drug: Acupuncture combined
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acupuncture combined with acupoint injection of nerve growth factor (NGF), 0.5 mL each acupoint, once a day for 7 days, 3 sessions total
Trial: 26521569
Drug: Intravenous drop
RxNorm normalized name: Amoxi Drop
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous drop of citicoline sodium and intramuscular injection of NGF, treatment for 7 days, 3 sessions total
Trial: 16897661
Drug: Structured Treatment
RxNorm normalized name: Lipid,structured (From Sunflower Oil)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Structured Treatment Interruption (STI)
Trial: 2487532
Drug: 150 mg
RxNorm normalized name: pectin 150 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 150 mg of ibopamine
Trial: 27046443
Drug: Skin/subcutaneous hypoperfusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Skin/subcutaneous hypoperfusion on ICG-FA
Trial: 25044423
Drug: Curcumin capsules
RxNorm normalized name: curcumin Oral Capsule
DrugBank: Curcumin sulfate (DB14635)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin capsules
Trial: 12679437
Drug: Glyburide therapy
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide therapy
Trial: 21542122
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous n-acetylcysteine (1,200 mg bolus followed by 200 mg/hr for 24 hr; n = 206)
Trial: 21542122
Drug: High-dose intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose intravenous n-acetylcysteine
Trial: 11467630
Drug: 50 mg
RxNorm normalized name: talc 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg erythromycin (Er50)
Trial: 11467630
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg erythromycin (Er100)
Trial: 9812643
Drug: Xianzhen tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xianzhen tablet
Trial: 7959083
Drug: Vitamin C,
RxNorm normalized name: Vitamin C, sodium salt
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C, 250 mg twice daily
Trial: 7959083
Drug: Placebo, one
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, one capsule twice daily
Trial: 3652479
Drug: Pirenzepine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pirenzepine (100 mg orally at 2200 and 2400 h)
Trial: 29617737
Drug: 200 µg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 200 µg/kg ivermectin
Trial: 29617737
Drug: 600 µg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 600 µg/kg ivermectin
Trial: 20863389
Drug: 40 mg/m²
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg/m² Cisplatin (group I; 16 patients)
Trial: 20863389
Drug: 50 mg/m²
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/m² Paclitaxel (group II; 15 patients)
Trial: 18395723
Drug: Soy isoflavones
RxNorm normalized name: Soy isoflavones
DrugBank: Soy isoflavones (DB14101)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Soy isoflavones (135 mg daily for 6 months)
Trial: 14551299
Drug: Standard timed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard timed (ST) doxorubicin 60 mg/m2 plus cisplatin 60 mg/m2
Trial: 14551299
Drug: Circadian timed
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Circadian timed (CT) doxorubicin 60 mg/m2 at 6:00 am plus cisplatin 60 mg/m2 at 6:00 pm
Trial: 10529079
Drug: Intracoronary papaverine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intracoronary papaverine (10 mg)
Trial: 4033706
Drug: High-protein diet
RxNorm normalized name: high-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-protein diet (268 g per day)
Trial: 4033706
Drug: Low-protein diet
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-protein diet (19 g per day)
Trial: 23897038
Drug: ondansetron (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ondansetron (4 mg/kg of body weight twice daily)
Trial: 16601642
Drug: Usual treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Usual treatment plus family psychoeducation
Trial: 11191690
Drug: Fluvoxamine with
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fluvoxamine with behavior therapy (20 sessions)
Trial: 1449045
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (hGH) 0.1 IU.kg‐1 body weight.d‐1
Trial: 1449045
Drug: recombinant human
RxNorm normalized name: Recombinant human TNF
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: recombinant human growth hormone (hGH)
Trial: 3904700
Drug: Alternative healing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alternative healing agents
Trial: 25371275
Drug: NSAID patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID patch (ketoprofen)
Trial: 25371275
Drug: NSAID patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID patch + TENS
Trial: 25371275
Drug: NSAID patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID patch + heating pad
Trial: 25371275
Drug: NSAID patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NSAID patch + topical capsaicin
Trial: 22260861
Drug: Amino acid
RxNorm normalized name: Amino Acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Amino acid mixture beverage (CHO/AA) consisting of 0.088 g cystine 2HCl, 0.043 g methionine, 0.086 g valine, 12.094 g isoleucine, 0.084 g leucine, and 100 g dextrose
Trial: 22260861
Drug: Control beverage
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control beverage (CHO) consisting of 100 g dextrose only
Trial: 20230319
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg plain bupivacaine
Trial: 20230319
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg hyperbaric ropivacaine with fentanyl 20 μg
Trial: 20230319
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg plain ropivacaine with fentanyl 20 μg
Trial: 17053207
Drug: Salmeterol/fluticasone propionate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/fluticasone propionate (50/500 micro g) twice daily
Trial: 17053207
Drug: Salmeterol (50
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol (50 micro g) twice daily
Trial: 1496838
Drug: CO2-bathing series
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CO2-bathing series with light-motion therapy
Trial: 6648053
Drug: Combined regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined regimen (2-mg tablet of salbutamol + 10 puffs of salbutamol inhalation)
Trial: 6648053
Drug: Salbutamol inhalation
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol inhalation (100 micrograms per puff)
Trial: 6648053
Drug: Salbutamol tablet
RxNorm normalized name: salbutamol
DrugBank: Albuterol (DB01001)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Salbutamol tablet
Trial: 6648053
Drug: Placebo (tablet
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (tablet and inhalation)
Trial: 25222428
Drug: CPAP and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP and standard therapy
Trial: 10577754
Drug: Intra-articular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular morphine
Trial: 24952044
Drug: Intra-articular morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intra-articular morphine and lidocaine
Trial: 21909946
Drug: Visual feedback
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Visual feedback (visualization of charts showing the progression of disease activity parameters) added to DMARDs therapy
Trial: 18453320
Drug: Oat cereal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oat cereal (5.7 g/day beta-glucan)
Trial: 7297020
Drug: 5 mg
RxNorm normalized name: talc 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5 mg carteolol
Trial: 7297020
Drug: 2.5 mg
RxNorm normalized name: biotin 2.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2.5 mg carteolol
Trial: 7297020
Drug: 15 mg
RxNorm normalized name: papain 15 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 15 mg carteolol
Trial: 7297020
Drug: 60 mg
RxNorm normalized name: opium 60 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 60 mg carteolol
Trial: 31270291
Drug: Insulin degludec
RxNorm normalized name: Insulin Degludec
DrugBank: Insulin degludec (DB09564)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Insulin degludec U100 (IDeg)
Trial: 31270291
Drug: Insulin glargine
RxNorm normalized name: Insulin Glargine
DrugBank: Insulin glargine (DB00047)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Insulin glargine U100 (IGla)
Trial: 24954805
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment (paclitaxel then UFT)
Trial: 24954805
Drug: Sequential treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential treatment (paclitaxel then S-1)
Trial: 24954805
Drug: UFT monotherapy
RxNorm normalized name: UFT
DrugBank: Tegafur-uracil (DB09327)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: UFT monotherapy
Trial: 23098579
Drug: Conventional radiotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional radiotherapy (CR) - 25 × 2 Gy over 5 weeks, with a sequential boost of 8 × 2 Gy over 2 weeks for BCS patients
Trial: 26711755
Drug: Daptomycin 6
RxNorm normalized name: Daptomycin
DrugBank: Daptomycin (DB00080)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daptomycin 6 mg/kg/day
Trial: 19730900
Drug: Standard therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard therapy (vancomycin 1 g every 12 h or antistaphylococcal penicillin 2 g every 4 h, both with gentamicin 1 mg/kg every 8 h for 4 days)
Trial: 7810090
Drug: Iso‐Mack retard
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iso‐Mack retard + Moduretic (diuretic)
Trial: 30001923
Drug: Fingolimod 0.5
RxNorm normalized name: fingolimod 0.5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fingolimod 0.5 mg once-daily
Trial: 28634650
Drug: Z-360 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Z-360 60 mg
Trial: 28634650
Drug: Z-360 120
RxNorm normalized name: Z-160
DrugBank: Z-160 (DB12743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Z-360 120 mg
Trial: 28634650
Drug: Z-360 240
RxNorm normalized name: Z-160
DrugBank: Z-160 (DB12743)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Z-360 240 mg
Trial: 20438578
Drug: PEG‐IFN monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN monotherapy at a dosage of 0.8 μg/kg per week (n = 12)
Trial: 20438578
Drug: PEG‐IFN (0.8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN (0.8 μg/kg per week) plus RIB (800‐1200 mg/d) (n = 12)
Trial: 23274785
Drug: PEG‐IFN monotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: PEG‐IFN monotherapy